Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints when Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus.

Sader HS, Rhomberg PR, Doyle TB, Flamm RK, Mendes RE.

J Clin Microbiol. 2018 Sep 26. pii: JCM.00777-18. doi: 10.1128/JCM.00777-18. [Epub ahead of print]

2.

Activity of fosfomycin when tested against US contemporary bacterial isolates.

Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D.

Diagn Microbiol Infect Dis. 2018 Aug 28. pii: S0732-8893(18)30304-3. doi: 10.1016/j.diagmicrobio.2018.08.010. [Epub ahead of print]

PMID:
30236530
3.

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.

Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL, Castanheira M.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01230-18. doi: 10.1128/AAC.01230-18. Print 2018 Oct.

4.

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.

Sader HS, Flamm RK, Dale GE, Rhomberg PR, Castanheira M.

J Antimicrob Chemother. 2018 Sep 1;73(9):2400-2404. doi: 10.1093/jac/dky227.

PMID:
29901750
5.

Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.

Pfaller MA, Rhomberg PR, Castanheira M.

Diagn Microbiol Infect Dis. 2018 Sep;92(1):43-45. doi: 10.1016/j.diagmicrobio.2018.04.005. Epub 2018 Apr 13.

PMID:
29735424
6.

Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.

Sader HS, Dale GE, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00311-18. doi: 10.1128/AAC.00311-18. Print 2018 Jul.

PMID:
29686157
7.

Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):179-183. doi: 10.1016/j.diagmicrobio.2018.01.019. Epub 2018 Feb 24.

PMID:
29571839
8.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK, Jones RN.

J Clin Microbiol. 2018 May 25;56(6). pii: e01960-17. doi: 10.1128/JCM.01960-17. Print 2018 Jun.

PMID:
29563198
9.

Erratum for Pfaller et al., "In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014".

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02383-17. doi: 10.1128/AAC.02383-17. Print 2018 Feb. No abstract available.

10.

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):143-147. doi: 10.1016/j.diagmicrobio.2017.10.010. Epub 2017 Oct 19.

PMID:
29157954
11.

In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program.

Flamm RK, Rhomberg PR, Sader HS.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01230-17. doi: 10.1128/AAC.01230-17. Print 2017 Dec.

12.

Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride.

Castanheira M, Duncan LR, Rhomberg PR, Sader HS.

Diagn Microbiol Infect Dis. 2017 Dec;89(4):305-309. doi: 10.1016/j.diagmicrobio.2017.08.011. Epub 2017 Aug 24.

PMID:
28969934
13.

Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.

Castanheira M, Deshpande LM, Davis AP, Rhomberg PR, Pfaller MA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00906-17. doi: 10.1128/AAC.00906-17. Print 2017 Oct.

14.

CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.

Pfaller MA, Messer SA, Rhomberg PR, Castanheira M.

Int J Antimicrob Agents. 2017 Sep;50(3):352-358. doi: 10.1016/j.ijantimicag.2017.03.028. Epub 2017 Jul 6.

15.

Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Pfaller MA, Messer SA, Rhomberg PR, Borroto-Esoda K, Castanheira M.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00161-17. doi: 10.1128/AAC.00161-17. Print 2017 Aug.

16.

Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.

Flamm RK, Farrell DJ, Rhomberg PR, Scangarella-Oman NE, Sader HS.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00468-17. doi: 10.1128/AAC.00468-17. Print 2017 Jul.

17.

WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.

Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M.

J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. doi: 10.1093/jac/dkx050.

PMID:
28333332
18.

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011.

Pfaller MA, Huband MD, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e00018-17. doi: 10.1128/AAC.00018-17. Print 2017 May.

19.

In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014.

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02609-16. doi: 10.1128/AAC.02609-16. Print 2017 Apr. Erratum in: Antimicrob Agents Chemother. 2018 Jan 25;62(2):.

20.

In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae.

Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02047-16. doi: 10.1128/AAC.02047-16. Print 2017 Mar.

21.

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.

Pfaller MA, Messer SA, Rhomberg PR, Castanheira M.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02045-16. doi: 10.1128/AAC.02045-16. Print 2017 Mar.

22.

Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe.

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02411-16. doi: 10.1128/AAC.02411-16. Print 2017 Mar.

23.

Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014).

Jones RN, Rhomberg PR, Mendes RE.

Diagn Microbiol Infect Dis. 2016 Oct;86(2):249-51. doi: 10.1016/j.diagmicrobio.2016.02.007. Epub 2016 Feb 9. No abstract available.

PMID:
27502927
24.

In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Flamm RK, Rhomberg PR, Huband MD, Farrell DJ.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5. doi: 10.1128/AAC.00941-16. Print 2016 Oct.

25.

Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.

Castanheira M, Rhomberg PR, Flamm RK, Jones RN.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5454-8. doi: 10.1128/AAC.00711-16. Print 2016 Sep.

26.

In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents.

Flamm RK, Rhomberg PR, Farrell DJ, Jones RN.

Diagn Microbiol Infect Dis. 2016 Sep;86(1):66-9. doi: 10.1016/j.diagmicrobio.2016.06.012. Epub 2016 Jun 16.

PMID:
27352729
27.

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.

Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M.

J Antimicrob Chemother. 2016 Oct;71(10):2868-73. doi: 10.1093/jac/dkw214. Epub 2016 Jun 10.

28.

Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).

Castanheira M, Messer SA, Rhomberg PR, Pfaller MA.

Diagn Microbiol Infect Dis. 2016 Jun;85(2):200-4. doi: 10.1016/j.diagmicrobio.2016.02.009. Epub 2016 Feb 9.

PMID:
27061369
29.

Comparison of BD Max StaphSR and BD Max MRSAXT for Screening of Staphylococcus aureus Clinical Isolates Collected from Hospitals in the United States.

Mendes RE, Watters AA, Rhomberg PR, Farrell DJ, Jones RN.

J Clin Microbiol. 2016 Jun;54(6):1668-1669. doi: 10.1128/JCM.00374-16. Epub 2016 Mar 23. No abstract available.

30.

Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.

Jones RN, Moeck G, Arhin FF, Dudley MN, Rhomberg PR, Mendes RE.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3174-7. doi: 10.1128/AAC.03029-15. Print 2016 May.

31.

Ceftaroline activity tested against viridans group streptococci from US hospitals.

Sader HS, Rhomberg PR, Castanheira M, Farrell DJ, Flamm RK, Mendes RE, Jones RN.

Diagn Microbiol Infect Dis. 2016 Mar;84(3):232-5. doi: 10.1016/j.diagmicrobio.2015.10.028. Epub 2015 Nov 3.

PMID:
26658313
32.

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.

Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y.

J Antimicrob Chemother. 2016 Mar;71(3):670-7. doi: 10.1093/jac/dkv402. Epub 2015 Dec 7.

PMID:
26645269
34.

Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide.

Sader HS, Rhomberg PR, Farrell DJ, Jones RN.

Diagn Microbiol Infect Dis. 2015 Dec;83(4):379-81. doi: 10.1016/j.diagmicrobio.2015.08.013. Epub 2015 Aug 28.

PMID:
26415906
35.

Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination.

Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR, Jones RN.

Antimicrob Agents Chemother. 2015 Dec;59(12):7823-5. doi: 10.1128/AAC.01021-15. Epub 2015 Sep 21.

36.
37.

Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.

Sader HS, Rhomberg PR, Farrell DJ, Jones RN.

Antimicrob Agents Chemother. 2015;59(6):3263-70. doi: 10.1128/AAC.04839-14. Epub 2015 Mar 23.

38.

Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.

Flamm RK, Rhomberg PR, Kaplan N, Jones RN, Farrell DJ.

Antimicrob Agents Chemother. 2015 May;59(5):2583-7. doi: 10.1128/AAC.05119-14. Epub 2015 Feb 17.

39.

In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.

Flamm RK, Rhomberg PR, Jones RN, Farrell DJ.

Antimicrob Agents Chemother. 2015 Apr;59(4):2280-5. doi: 10.1128/AAC.04840-14. Epub 2015 Feb 2.

40.

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species.

Pfaller MA, Rhomberg PR, Messer SA, Castanheira M.

Diagn Microbiol Infect Dis. 2015 Apr;81(4):259-63. doi: 10.1016/j.diagmicrobio.2014.11.008. Epub 2014 Nov 25.

PMID:
25600842
41.

In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms.

Flamm RK, Rhomberg PR, Simpson KM, Farrell DJ, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2015 Mar;59(3):1751-4. doi: 10.1128/AAC.04773-14. Epub 2015 Jan 12.

42.

Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone.

Jones RN, Holliday NM, Rhomberg PR.

J Clin Microbiol. 2015 Feb;53(2):657-9. doi: 10.1128/JCM.02769-14. Epub 2014 Nov 19.

43.

Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease.

Barriere SL, Farrell DJ, Rhomberg PR, Jones RN.

Diagn Microbiol Infect Dis. 2014 Dec;80(4):327-9. doi: 10.1016/j.diagmicrobio.2014.09.002. Epub 2014 Sep 6.

44.

Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.

Farrell DJ, Mendes RE, Rhomberg PR, Jones RN.

Antimicrob Agents Chemother. 2014 Sep;58(9):5547-51. doi: 10.1128/AAC.03172-14. Epub 2014 Jul 14.

45.

Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.

Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA.

Mycopathologia. 2014 Aug;178(1-2):1-9. doi: 10.1007/s11046-014-9772-2. Epub 2014 Jun 21.

PMID:
24952015
46.

Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics.

Montgomery AB, Rhomberg PR, Abuan T, Walters KA, Flamm RK.

Antimicrob Agents Chemother. 2014 Jul;58(7):3708-13. doi: 10.1128/AAC.02779-13. Epub 2014 Apr 21.

47.

Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.

Montgomery AB, Rhomberg PR, Abuan T, Walters KA, Flamm RK.

Antimicrob Agents Chemother. 2014 Jul;58(7):3714-9. doi: 10.1128/AAC.02780-13. Epub 2014 Apr 21.

48.

Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.

Pfaller MA, Castanheira M, Messer SA, Rhomberg PR, Jones RN.

Diagn Microbiol Infect Dis. 2014 Jun;79(2):198-204. doi: 10.1016/j.diagmicrobio.2014.03.004. Epub 2014 Mar 17.

PMID:
24736096
49.

Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.

Sader HS, Rhomberg PR, Jones RN.

Antimicrob Agents Chemother. 2014;58(4):2434-7. doi: 10.1128/AAC.02398-13. Epub 2014 Jan 21.

50.

In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.

Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M.

J Clin Microbiol. 2013 Aug;51(8):2608-16. doi: 10.1128/JCM.00863-13. Epub 2013 Jun 5.

Supplemental Content

Loading ...
Support Center